Sanofi has announced positive results of its combination drug LixiLan phase III trials for Type 2 diabetes. Constituted from both Lixisenatide and insulin glargine Lantus, LixiLan is developed to tackle type 2 diabetes when both oral medication fails and basal insulin loses its efficacy.
Lixisenatide (Lyxumia outside the US) was initially discovered by Zealand Pharma, who licensed out the drug to Sanofi for development as a once-per-day injection of a prandial GLP-1 agonist (which stimulates an increase in insulin secretion, lowering blood glucose). However, competition of Lixisenatide side-project was already fierce, with Victoza by Novo Nordisk already being a super-GLP-1-agonist blockbuster. Novo continues to plod on in its pursuit of global diabetes domination against Sanofi, particularly motivated in the lead up to World Diabetes Day.
Lantus, on the other hand, is the long-acting insulin glargine analog giant, also administered once daily to lower blood glucose. Previously unrivaled, Lantus has dominated the market for years, earning Sanofi up to €6.2Bn last year in revenue. However, since the Lantus patent expired in February of this year,